Idasanutlin (Standard)

[1]. Tang G, et al.. Repurposing MDM2 inhibitor RG7388 for TP53-mutant NSCLC: a p53-independent pyroptotic mechanism via ROS/p-p38/NOXA/caspase-3/GSDME axis. Cell death & disease. 2025 Jun 17;16(1):452. [Content Brief]

[2]. Johansson KB, et al.. Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia. 2023 Dec;37(12):2356-2366. [Content Brief]

[3]. Nieznanska A, et al.. Balancing cell cycle arrest and immune activation: A synergistic window for idasanutlin and anti-PD-1 therapy in a syngeneic mouse model. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2025 Dec;193:118868. [Content Brief]

[4]. Herting F, et al. The triple combination of the CD20 antibody obinutuzumab with the Bcl-2 inhibitor venetoclax (GDC-199) and the MDM2 inhibitor idasanutlin results in superior efficacy and long term response in wildtype p53 NHL tumor models. Blood. 2016 Dec 2;128(22):4178.

[5]. Liu Z, et al.. RG7388 inhibits SFTSV replication by suppressing MDM2-mediated p53 degradation and preventing apoptosome disruption. Science Bulletin. 2025 Jun 21. [Content Brief]

[6]. Vernooij L, et al.. High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells. Molecular cancer therapeutics. 2021 Jun;20(6):1161-1172. [Content Brief]

[7]. Gu JJ, et al.. Targeting MDM2 and XIAP by Idasanutlin in diffuse large B-cell lymphoma. Blood. 2019 Nov 13;134:5301.

[8]. Bell HL, et al. Preclinical investigation of the p53-MDM2 antagonist idasanutlin (RG7388) demonstrates significant activity in high risk adult acute lymphoblastic leukemia. Blood. 2020 Nov 5;136:38.

[9]. Daver NG, et al.. Safety, efficacy, pharmacokinetic (PK) and biomarker analyses of BCL2 inhibitor venetoclax (Ven) plus MDM2 inhibitor idasanutlin (idasa) in patients (pts) with relapsed or refractory (R/R) AML: a phase Ib, non-randomized, open-label study. Blood. 2018 Nov 29;132:767.

[10]. Ding Q, et al. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. Journal of medicinal chemistry. 2013 Jul 25;56(14):5979-83. [Content Brief]

[11]. Higgins B, et al. Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Jul 15;20(14):3742-52. [Content Brief]

[12]. Lehmann C, et al.. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. Journal of hematology & oncology. 2016 Jun 28;9(1):50. [Content Brief]